On August 19, 2024 Peptomyc S.L., a company developing foundational mini-protein therapeutics for the treatment of cancer, reported that the Company has been issued a patent by the Hong Kong Patent Office protecting its Methods and Composition of Matter (Press release, Peptomyc, AUG 19, 2024, View Source [SID1234645985]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to announce further protection of our mini-protein therapeutics in Hong Kong. This patent grant strengthens our patent portfolio that protects our unique mini-protein therapeutics, which are able to inhibit MYC, the most dysregulated oncogene in human cancer, in the major geographical areas in oncology," said Laura Soucek, CEO at Peptomyc S.L.

The Company currently maintains over 10 different patent families worldwide covering applications protecting Peptomyc S.L. first-in-modality mini-protein therapeutics in multiple oncological indications, and counts on the services of ABG Intellectual Property and Dechert LLP for the protection of its IP assets.